Puma Biotechnology Inc Stock Price, News & Analysis

Puma Biotechnology (NASDAQ: PBYI) has initiated the ALISCA™-Breast1 Phase II trial of alisertib combined with endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer patients. The study will enroll up to 150 patients who have previously received CDK 4/6 inhibitors and at least two prior endocrine therapies. Patients will be randomized to receive alisertib at 30mg, 40mg, or 50mg doses. The trial's primary endpoints include objective response rate, duration of response, disease control rate, progression-free survival, and overall survival. Initial data is expected in 2025, with plans to discuss potential approval pathways with the FDA following trial outcomes.

Puma Biotechnology (NASDAQ: PBYI) reported strong Q3 2024 financial results with total revenue of $80.5 million, including $56.1 million in product revenue from NERLYNX® and $24.4 million in royalty revenue. The company posted a net income of $20.3 million ($0.41 per share), up from $5.8 million in Q3 2023. Operating cash flow was $11.0 million, with cash and equivalents of $97 million. The company updated its full-year 2024 guidance, projecting net product revenue of $187-190 million and net income of $15-17 million.

Puma Biotechnology (NASDAQ: PBYI) announced the approval of an inducement restricted stock unit award of 5,625 shares to a new non-executive employee. The award, granted under the company's 2017 Employment Inducement Incentive Award Plan, will vest over three years, with one-third vesting after the first year and one-sixth every six months thereafter, starting from November 1, 2024. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Puma Biotechnology (NASDAQ:PBYI) announced it will host a conference call on Thursday, November 7, 2024, at 1:30 p.m. PST/4:30 p.m. EST to discuss its third quarter 2024 financial results. Participants can join via phone using 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's website, with a replay accessible for 90 days.

Puma Biotechnology (NASDAQ: PBYI) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City. Alan H. Auerbach, the company's Chairman, CEO, President, and Founder, will present an overview of Puma Biotechnology on Monday, September 9, at 3:00 p.m. EDT.

Investors and interested parties can access a live webcast of the presentation through the company's website at pumabiotechnology.com. The presentation will remain available on the website for 30 days after the event, providing an opportunity for those unable to attend the conference to gain insights into Puma Biotechnology's current status and future plans.

Puma Biotechnology (NASDAQ: PBYI) has granted an inducement restricted stock unit award to a new non-executive employee. The award, approved on August 5, 2024, covers 3,500 shares of Puma common stock. This grant falls under Puma's 2017 Employment Inducement Incentive Award Plan, adopted on April 27, 2017. The award will vest over three years, with one-third vesting on August 1, 2025, and one-sixth vesting every six months thereafter, contingent on continued employment. This award is in compliance with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for the new employee to join Puma.

Puma Biotechnology (NASDAQ: PBYI) reported its Q2 2024 financial results. Product revenue from NERLYNX® sales was $44.4 million, down from $51.6 million in Q2 2023. The company reported a net loss of $4.5 million, or $0.09 per share, compared to net income of $2.1 million in Q2 2023. Non-GAAP adjusted net loss was $2.5 million. Total revenue for Q2 2024 was $47.1 million, including $2.7 million in royalty revenue. Operating costs were $49.3 million. The company ended the quarter with $96.8 million in cash and equivalents. Puma anticipates key milestones in the next 12 months, including the initiation of ALISCA™-Breast1 trial and interim data from ALISCA™-Lung1 trial. The company provided guidance for Q3 and full-year 2024, projecting net product revenue of $183-$190 million for the year.

Puma Biotechnology (NASDAQ: PBYI) has announced a conference call to discuss its second quarter 2024 financial results. The call is scheduled for Thursday, August 1, 2024, at 1:30 p.m. PDT/4:30 p.m. EDT. Investors can access the call by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's website. The call replay will be archived on Puma's website for 90 days after the event.

Puma Biotechnology announced that its Compensation Committee approved the grant of an inducement restricted stock unit (RSU) award covering 3,500 shares of common stock to a new non-executive employee. This decision was made on July 1, 2024, under its 2017 Employment Inducement Incentive Award Plan. The RSU award will vest over three years, with one-third of the shares vesting on the first anniversary, and one-sixth vesting every six months thereafter. This grant was made as an inducement material for the new employee according to Nasdaq Listing Rule 5635(c)(4).